Gliclada tablets with prolonged release 60 mg. №30


Manufacturer: Slovenia

The drug is indicated for Gliklad: type II diabetes: reducing and controlling blood glucose levels when it is not possible to normalize it by diet and exercise; prevention of complications of type II diabetes: reducing the risk of macro-and microvascular complications, worsening of nephropathy in patients with type II diabetes.



Gliclada Composition
active substance: gliclazide;

1 modified release tablet contains 60 mg of gliclazide;

excipients: hypromellose, lactose, colloidal silicon dioxide, magnesium stearate.

Gliclada Dosage form
Modified release tablets.

Basic physical and chemical properties: tablets from white to almost white, oval, biconvex.

Gliclada Pharmacotherapeutic group
Antidiabetic drugs. Sugar reducing agents, with the exception of insulin. Sulfonamides, urea derivatives. Gliclazide. ATX code А10В В09.

Gliclazide is an oral hypoglycemic drug, a sulfonylurea derivative, which differs from other drugs by the presence of a heterocyclic ring containing nitrogen and has endocyclic bonds.

Gliclazide reduces the level of glucose in the blood plasma due to the stimulation of insulin secretion by β-cells of the islets of Langerhans of the pancreas. The increase in the level of postprandial insulin and the secretion of C-peptide persist even after 2 years of using the drug. Gliclazide also has hemovascular properties.

Influence on insulin secretion.

In patients with type II diabetes, gliclazide restores the early peak of insulin secretion in response to glucose intake and increases the second phase of insulin secretion. A significant increase in insulin secretion occurs in accordance with food intake or glucose load.

Type II diabetes mellitus in adults:

lowering and controlling blood glucose if it is impossible to normalize glucose levels only by diet, exercise or weight loss;
prevention of complications of type II diabetes mellitus: reducing the risk of macro- and microvascular complications, including new cases or worsening of nephropathy in patients with type II diabetes mellitus who are treated according to the strategy of intensive glycemic control.

Hypersensitivity to gliclazide or to another sulfonylurea drug, sulfonamides, or to any component of the drug;
diabetes mellitus (type I);
diabetic coma and coma, diabetic ketoacidosis;
severe hepatic or renal impairment (in this case, the use of insulin is recommended);
treatment with miconazole (see the section “Interaction with other medicinal products and other types of interactions”);
lactation period.